What Bloom Technology does

Bloom Technology Corporation is a Japanese privately-held drug discovery company founded on November 19, 2014 and headquartered in Kumamoto, Japan. The company is built around a proprietary scientific platform targeting Toxic Advanced Glycation End-products (TAGE/Glycer-AGEs), the toxic subset of advanced glycation end-products implicated in lifestyle-related diseases. Bloom Technology claims to be the first organization in the world to elucidate the chemical structure of TAGE and to generate monoclonal antibodies against this structure, and it is developing anti-TAGE antibody therapeutics aimed at diabetic retinopathy, diabetic nephropathy, and non-alcoholic steatohepatitis (NASH), with potential extension to cardiovascular disease, cancer, infertility, and Alzheimer's disease.

The company's commercial offerings comprise three lines: a core pipeline of anti-TAGE therapeutic monoclonal antibodies supported by preclinical proof-of-concept data in diabetes and NASH model mice; a TAGE blood concentration measurement service launched in September 2017 for research customers; and a small online consumer health products shop (Bloom Tech Online Shop) launched in July 2015. Its go-to-market is sales-led and research-relationship-driven: the company engages pharmaceutical companies and academic institutions through commissioned research agreements, participates in scientific conferences, and has built an extensive network of joint research agreements with Japanese universities including Kumamoto University, Niigata University of Pharmacy and Applied Life Sciences, Chiba University Graduate School of Medicine, Kanazawa Medical University, and Tokai University.

Revenue mechanics are predominantly professional services (fee-for-service testing and commissioned research) with no publicly disclosed pricing, complemented by a theoretical future stream of licensing royalties on anti-TAGE antibody IP. The company has raised approximately 330 million yen in cumulative disclosed funding across a 2018 Nissay Capital-led round (200 million yen) and a 2019 third-party share allocation (130 million yen), with stated capital of 30.5 million yen as of March 31, 2021. Headcount is 1-10 employees, no parent or controlling shareholder is disclosed, and leadership is anchored by CEO Tetsuro Yamamoto (former Kumamoto University pathology professor, M.D./Ph.D.) and Director Tamami Sakamoto.

Name

Bloom Technology

Legal name

Bloom Technology株式会社

Website

https://bloom-technology.co.jp

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Bloom Technology is a Kumamoto-based Japanese biotech founded in 2014 that develops anti-TAGE monoclonal antibody therapeutics for diabetes complications and NASH, and offers TAGE blood concentration measurement services to pharmaceutical and academic research customers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Discovery

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Diabetes (General) (HLAKADAA), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

Keywords

• Drug discovery
• Monoclonal antibodies
• Toxic-AGEs therapeutics
• Contract research services
• Biomarker measurement

Headquarters

HQ city

Kumamoto

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Commissioned Research Services: Fee-for-service research collaborations with academic institutions and pharmaceutical companies for TAGE-related drug discovery and development.
2. Contract Testing Services: Fee-based measurement services for TAGE blood concentration analysis provided to research customers.
3. Licensing Royalties: Potential future revenue from licensing anti-TAGE therapeutic technologies and monoclonal antibody discoveries.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Bloom Technology is a Japanese drug discovery company developing anti-TAGE (Toxic Advanced Glycation End-products, also known as Glycer-AGEs) monoclonal antibody therapeutics targeting diabetes complications such as retinopathy and nephropathy, as well as non-alcoholic steatohepatitis (NASH). The company also operates a commissioned TAGE blood concentration measurement service for academic and pharmaceutical research customers and runs an online shop (Bloom Tech Online Shop) for consumer health-related products.

Product overview

Bloom Technology is a drug discovery company developing anti-TAGE (toxic advanced glycation end-products) therapeutics and offering contract measurement services for TAGE research. The company operates three main offerings: Toxic-AGEs measurement services for research institutions, anti-TAGE monoclonal antibody drug development targeting diabetic complications and NASH, and a consumer health products online shop.

Differentiator

Problem solved

Functional benefit

Products and services

• Toxic-AGEs Measurement Services (受託測定サービス) Contract measurement service for detecting Toxic-AGEs (TAGE) concentration in blood samples, offered to academic research institutions and pharmaceutical companies for research applications such as biomarker development and lifestyle-disease studies.
• Anti-TAGE Antibody Drug Development Preclinical-stage therapeutic program developing proprietary monoclonal antibodies against Toxic-AGEs (TAGE/Glycer-AGEs) for treatment of diabetic retinopathy, diabetic nephropathy, and non-alcoholic steatohepatitis (NASH), pursued through joint research with academic institutions and pharmaceutical partners.
• Bloom Tech Online Shop (ブルームテックオンラインショップ) Online sales platform offering health-related products developed or curated by the company to consumers.

Quantifiable outcome

• Anti-TAGE antibody administration alleviated retinal abnormalities in diabetes model mice
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

13 partnerships are on record, tiered core, minor and major.

• NAVER CloudcoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI combining NAVER Cloud's AI agent technology with Bloom Technology's Locus Chain blockchain for next-generation AI integrated platform development enabling AI avatars to autonomously manage real-world and virtual activities.
• CretacoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI, a next-generation AI integrated platform designed to expand human experience across real and virtual worlds through AI avatars.
• EOGroundcoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI consortium developing AI-powered digital ecosystem platform.
• Lloyds CapitalcoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI consortium developing AI-powered digital ecosystem platform.
• Nexus Core SystemscoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI consortium developing AI-powered digital ecosystem platform combining AI agents with blockchain technology.
• Kumamoto Prefecture Agricultural Research Center (熊本県農業研究センター)minorStrategic or Co-development Partner · 16 September 2016Joint research agreement for TAGE research with agricultural research applications.
• Kumamoto University Institute of Resource Development and Analysis (熊本大学生命資源研究支援センター)majorStrategic or Co-development Partner · 1 June 2016Joint research agreement for TAGE research development.
• Tokai University School of Agriculture (東海大学農学部)majorStrategic or Co-development Partner · 1 August 2015Joint research agreement for germ cell preservation drug development.
• Kanazawa Medical University Medical Research Institute (金沢医科大学総合医学研究所)majorStrategic or Co-development Partner · 3 June 2015Funded research agreement for TAGE development research.
• Cell Science & Technology Institute (細胞科学研究所)minorStrategic or Co-development Partner · 1 June 2015Affiliation/partnership for cell science research collaboration.
• Chiba University Graduate School of Medicine (千葉大学大学院医学部)majorStrategic or Co-development Partner · 1 May 2015Joint research agreement for drug development collaboration.
• Kumamoto University Research Institute for Drug Discovery (熊本大学創薬研究センター)majorStrategic or Co-development Partner · 1 April 2015Joint research agreement for drug development, focusing on pharmaceutical development research.
• Niigata University of Pharmacy and Applied Life Sciences (新潟薬科大学)majorStrategic or Co-development Partner · 1 December 2014Joint research agreement to test efficacy of healthcare products, focusing on Health Care product development.

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Eli Lilly: Major US-based pharmaceutical innovator with an aggressive metabolic disease pipeline (including GLP-1 franchise in diabetes/obesity and active MASH programmes), establishing the competitive landscape and partnership benchmark for novel mechanisms like TAGE-targeted antibodies.
• Daiichi Sankyo: Top-tier Japanese pharmaceutical innovator with active R&D in metabolic and cardiovascular disease and well-established global licensing/partnering infrastructure, relevant both as a potential partner and as a comparable for biotech pipeline value in Japan.
• Takeda Pharmaceutical: Japan's largest pharmaceutical company with historical leadership in diabetes therapeutics and a global rare-disease and metabolic pipeline, frequently engaging in Japanese biotech licensing transactions that serve as a benchmark partnership template for early-stage Japanese biotechs.
• Novo Nordisk: Global leader in diabetes and obesity therapeutics with the deepest commercial franchise in the cardiometabolic indications where Bloom's anti-TAGE antibody would compete, making it a critical potential partner or competitive threat.
• Mitsubishi Tanabe Pharma: Major Japanese pharmaceutical company with a traditional diabetes and metabolic disease commercial footprint and frequent Japanese biotech partnering activity, providing another realistic potential acquirer or licensee for Bloom's anti-TAGE assets.
• Astellas Pharma: Major Japanese pharmaceutical company with a substantial diabetes and metabolic disease franchise (historically including products in the diabetic complications space) and significant biopharmaceutical discovery capabilities, making it a likely potential licensing or acquisition counterparty for Bloom's pipeline.

Direct peers

• Alteon: Historically the most prominent anti-AGE biopharma, developing alagebrium (ALT-711), an AGE crosslink breaker, for cardiovascular complications of diabetes. Despite being a direct scientific predecessor to Bloom's TAGE approach, Alteon illustrates the translation challenges of anti-AGE therapeutics.
• Kissei Pharmaceutical: Mid-cap Japanese specialty pharmaceutical company focused on diabetes, kidney disease, and related metabolic disorders, directly comparable in therapeutic focus to Bloom and representative of the typical Japanese partner profile for an early-stage metabolic biotech.
• vTv Therapeutics: Clinical-stage US biopharma that developed azeliragon, a RAGE receptor antagonist for Alzheimer's disease, making it one of the closest direct comparables to Bloom Technology's anti-TAGE/anti-RAGE-pathway antibody strategy in metabolic/neurodegenerative indications.

Regional players

• Mochida Pharmaceutical: Mid-sized Japanese pharmaceutical company with metabolic and specialty franchises (including diabetes adjacencies), representative of the regional partner pool where a small Japanese biotech like Bloom could secure a domestic out-licensing deal.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bloom Technology